First Commercially Available Droplet Digital PCR Solution for Detecting Pathogenic STEC
HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of its dd-Check STEC Solution for detecting virulence genes from Shiga toxin-producing Escherichia coli (STEC). Pathogenic STEC is defined as the presence of both stx1 and stx2, as well as eae, in one E. coli bacterium. The kit, which harnesses Bio-Rad’s Droplet Digital PCR (ddPCR) technology, is the first commercially available test for determining the coexistence of the STEC virulence genes in a single bacterium, providing rapid and reliable confirmation of the presence of pathogenic STEC.
Traditional screening tests for pathogenic STEC cannot distinguish between bacteria carrying both virulence markers (true positive) and mixed cultures in which these target genes are present in different bacteria (false positive). After a traditional screening test, samples must go through laborious culture methods to confirm results, which can take up to five days.
Since dd-Check STEC Solution accurately determines the coexistence of stx and eae in the same bacterium without additional confirmatory steps, it can return results in a few hours. Decreasing screening and confirmation turnaround time means products can be released to market faster, which is especially important for food matrices with limited shelf life.
The dd-Check STEC Solution uses ddPCR technology to generate thousands of uniform nanoliter-sized droplets. Once generated, the droplets can be amplified, read, and analyzed for the colocalization of virulence genes by Bio-Rad Qx IDE Manager Software. By encapsulating a single bacterium in each droplet, the dd-Check STEC Kit can distinguish between a true positive and a negative result.
As regulations classifying STEC as an adulterant continue to change, the kit provides the flexibility to adapt to new requirements. If other virulence factors are required for testing, the workflow can be updated to include additional testing.
To learn more about the dd-Check STEC Solution, visit bio-rad.com/ddcheck.
BIO-RAD, DDPCR, DROPLET DIGITAL, and DROPLET DIGITAL PCR are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.2 billion in 2018. For more information, please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Press Contact:
Bio-Rad Laboratories, Inc.
Wendy Lauer
510-741-5653
wendy_lauer@bio-rad.com
CG Life
Ken Li
312-997-2436
kli@cglife.com